<DOC>
	<DOCNO>NCT00238524</DOCNO>
	<brief_summary>This trial conduct 50 site Europe clinically complete . Patients symptoms painful diabetic neuropathy 6 month 5 year optimize diabetic control least moderate pain . Patients eligible chronic pain medical psychiatric condition , would jeopardize compromised patient 's ability participate trial . After 2-week run-in phase patient randomly assign one three treatment arm . All patient complete 6-week titration phase reach target dose enter 12-week maintenance phase . At end maintenance phase , subject offer option enter open-label , follow-on trial . The change pain measure daily well interference pain sleep general activity .</brief_summary>
	<brief_title>A Trial Assess Efficacy Safety SPM 927 ( Lacosamide ) Subjects With Painful Distal Diabetic Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Painful distal diabetic neuropathy Symptoms painful distal diabetic neuropathy less six month great 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>painful distal diabetic neuropathy</keyword>
</DOC>